title: Evaluation of clinical outcomes in patients undergoing dual vessel percutaneous coronary intervention using sirolimus-eluting coronary stent system in India.
abstract: BACKGROUND
  Coronary artery disease is the most common catastrophic disease in India. The safety and effectiveness of dual vessel sirolimus-eluting stent (SES) implantation (used as an intervention in CAD) is currently unknown in Indian population. The purpose of this study was to investigate one year clinical outcomes of patients with dual vessel coronary artery disease after implantation of the Supralimus-Core SES, in a "real-world" setting.
  
  
  METHODS
  We evaluated 60 patients between April-2011 and August-2012, who underwent dual vessel percutaneous coronary intervention (PCI) with the Supralimus-Core SES implantation at the same index procedure. Dual vessels were defined as involvement of two major epicardial vessels (right, left anterior descending, circumflex, or left main coronary arteries) or one major epicardial vessel and a branch (≥2.5 mm in diameter) originating from another major epicardial vessel. The primary endpoint was target lesion failure (TLF) defined as the composite of cardiac death, myocardial infarction (MI), and clinically-driven target lesion revascularization (TLR) at one year. Secondary endpoint included combined (definite, probable and possible) stent thrombosis (ST).
  
  
  RESULTS
  A total of 120 lesions were treated in 60 enrolled patients (mean age 56.0±9.2 y; 80.0% male) with average stent length of 23.1±8.5 mm. Among 60 patients, diabetes, hypertension and hypercholesterolemia were present in 15 (25.0%), 22 (36.7%) and 25 (41.7%) patients respectively. Indications for PCI were unstable angina in 30 (50.0%) patients and stable angina in 11 (18.3%) patients. Overall, 40 (33.3%) lesions were classified as complex (American College of Cardiology/American Heart Association type B2/C). The cumulative TLF rate was 5.0% (n=3) at one year. Cardiac death, MI and clinically-driven TLR occurred in 1 (1.7%), 0 (0%) and 2 (3.3%) patients, respectively at one year follow-up. The Kaplan-Meier curve of the freedom from overall events at one year was 95.0%. According to the Academic Research Consortium definition, there were no events of stent thrombosis during one year.
  
  
  CONCLUSIONS
  Our study shows that, dual vessel Supralimus-Core SES implantation allows safe and effective treatment with low rates of TLF at one year follow-up in Indian population.
authors: Director, Department of Cardiology, Heart and General Hospital , 7, Vivekanand Marg, C-Scheme, Jaipur, India .
authors: Prakash
authors: P
authors: Chandwani
authors: Senior Interventional Cardiologist, Department of Cardiology, Apollo Hospitals International Limited , Gandhinagar, Gujarat, India. .
authors: Jayesh
authors: J
authors: Prajapati
authors: Associate Professor, Department of Cardiology, KLEs Dr. Prabhakar Kore Hospital & Medical Research Centre , Belgaum, Karnataka, India .
authors: Sanjay
authors: S
authors: Porwal
authors: Senior Clinical Research Associate, Department of Clinical Trials, Sahajanand Medical Technologies Pvt. Ltd , Surat, Gujarat, India .
authors: Bhavesh
authors: B
authors: Khambhati
authors: Senior Manager, Clinical Research and Medical Writing, Department of Clinical Trials, Sahajanand Medical Technologies Pvt. Ltd , Surat, Gujarat, India .
authors: Ashok
authors: A
authors: Thakkar
keywords: Coronary artery disease; Dual vessel disease; Sirolimus-eluting stent